T-helper 17 signaling pathway (Th17 pathway) (Th17 pathway)

The T-helper 17 (Th17) signaling pathway is a specialized arm of the adaptive immune system defined by the differentiation of naive CD4+ T cells into Th17 cells (StatPearls, 2023). These cells are characterized by the secretion of pro-inflammatory cytokines, most notably Interleukin-17A (IL-17A), IL-17F, and IL-22 (Nature Reviews Immunology, 2020). The differentiation and maintenance of the Th17 lineage are driven by a cytokine milieu including IL-6, TGF-β, and IL-23, which activate the master transcription factor Retinoic acid receptor-related orphan receptor gamma t (RORγt) (PubMed, 2021). While this pathway is essential for host defense against extracellular bacteria and fungi at mucosal surfaces, its dysregulation is a primary driver of chronic inflammatory and autoimmune diseases (Journal of Clinical Investigation, 2022). Conditions such as psoriasis, ankylosing spondylitis, and psoriatic arthritis are heavily dependent on Th17-mediated inflammation (The Lancet, 2021). Therapeutic strategies targeting this pathway involve monoclonal antibodies that either neutralize the cytokines themselves or block their cognate receptors (e.g., IL-17RA) (FDA, 2024). Drugs like Secukinumab and Ixekizumab have shown high efficacy in treating these conditions by interrupting the IL-17/IL-23 axis (NEJM, 2022). However, inhibition of this pathway requires monitoring for safety concerns, including an increased susceptibility to mucocutaneous candidiasis and potential worsening of inflammatory bowel disease (Nature Reviews Rheumatology, 2023).

Other names

Th17 cell differentiation pathwayIL-17/IL-23 axisT-helper 17 cell signalingInterleukin-17 signaling pathway

Neutralization of pro-inflammatory cytokines (IL-17A, IL-17F, IL-23) or blockade of their receptors (IL-17RA) to inhibit downstream inflammatory signaling and Th17 cell maintenance.